Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 49 points (0.3%) at 16,147 as of Friday, Nov. 29, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,869 issues advancing vs. 987 declining with 109 unchanged. The Health Services industry currently sits up 0.3% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Opko Health ( OPK), up 2.3%, and Smith & Nephew ( SNN), up 0.7%. On the negative front, top decliners within the industry include Boston Scientific ( BSX), down 0.7%, Grifols ( GRFS), down 0.6% and Quest Diagnostics ( DGX), down 0.5%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.25 (0.7%) to $35.01 on light volume. Thus far, 19,451 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 137,800 shares. The stock has ranged in price between $34.69-$35.06 after having opened the day at $34.74 as compared to the previous trading day's close of $34.76. Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $20.9 billion and is part of the health care sector. The company has a P/E ratio of 18.0, above the S&P 500 P/E ratio of 17.7. Shares are up 1.3% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold. TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.